Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir, and ritonavir

Pharmacy World and Science

Volumn 19, Issue 4, 1997, Pages 159-175

  Hoetelmans, R M W ^a   Meenhorst, P L ^a   Mulder, J W ^a   Burger, D M ^b   Koks, C H W ^a   Beijnen, J H ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical pharmacology; HIV infection; Indinavir; Protease inhibitor; Ritonavir; Saquinavir

Indexed keywords

ALPRAZOLAM; ASTEMIZOLE; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; CLINDAMYCIN; DAPSONE; DEXAMETHASONE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; PROTEINASE; PROTEINASE INHIBITOR; QUINIDINE; RANITIDINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TERFENADINE; TRIAZOLAM; TRIMETHOPRIM; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; BIOAVAILABILITY; CLINICAL PHARMACOLOGY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHARMACODYNAMICS; REVIEW; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CLINICAL TRIALS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; RITONAVIR; SAQUINAVIR;

EID: 0030756358     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008629608556     Document Type: Review

References (99)

1. Centers for Disease Control. Pneumocystis pneumonia - Los Angeles. MMWR 1981;30:2.
2. Centers for Disease Control. Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York city and California. M M WR 1981;30:305-8.
3. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of 3′-amino-3′-deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl JMed 1987;317:185-91.
4. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
5. Hammer S, Katzenstein D, Hughes M, Gundacker H, Hirsch M, Merigan T. Nucleoside monotherapy (MT) vs. combination therapy (CT) in HIV infected adults: a randomized, double-blind, placebo-controlled trial in persons with CD4 cell counts 200-500/mm3. V European Conference on Clinical Aspects and Treatment of HIV Infection, fifth plenary session, Copenhagen, September 1995.
6. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A28.
7. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993;6:162-70.
8. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-90.
9. Winslow DL, Otto MJ. HIV protease inhibitors. AIDS 1995;9 Suppl A:S183-S192.
10. Kay J, Dunn BM. Viral proteinases: weakness in strength. Biochim Biophys Acta 1990;1048:1-18.
11. Copeland TD, Oroszlan S. Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. Gene Anal Tech 1988;5:109-15.
12. Tomasselli AG, Hui JO, Sawyer TK, Staples DJ, Bannow C, Reardon IM, et al. Specificity and inhibition of proteases from human immunodeficiency virus 1 and 2. J Biol Chem 1990;265:14675-83.
13. Darke PL, Huff JR. HIV protease as an inhibitor target for the treatment of AIDS. Adv Pharmacol 1994;25:399-454.
14. Miller M, Jaskólski M, Rao JKM, Leis J, Wlodawer A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (Lond) 1989;337:576-9.
15. Wlodawer A, Miller M, Jaskólski M. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989;245:616-21.
16. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996;51:701-12.
17. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-5.
18. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996;52:93-112.
19. Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal M J, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039-50.
20. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl JMed 1996;334:1011-7.
21. Vella S, Galluzzo C, Giannini G, et al. Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV straines with reduced phenotypic sensitivity. Antiviral Res 1996;29:91-3.
22. Lalezari J, Haubrich R, Burger HU, Beattie D, Donatacci L, Salgo MP, and the NV 14256 Study Team. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase™, SQV) plus Hivid (zalcitabine, ddC). XI International Conference on AIDS, Vancouver, July 1996, LB.B.6033.
23. Salgo MP, Beattie D, Bragman K, Donatacci L, Jones M, Montgomery L, the NV 14256 Study Team. Saquinavir (Invirase, SQV) vs. Hivid (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take Retrovir (zidovudine (ZDV). XI International Conference on AIDS, Vancouver, July 1996, Mo.B.410.
24. Baruch A, Mastrodonato-Delora P, Schnipper E, Salgo M. Efficacy and safety of triple combination therapy with Invirase (saquinavir/SQV/HIV protease inhibitor), Epivir (3TC/lamivudine) and Retrovir® (ZDV/zidovudine) in HIV-infected patients. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.172.
25. Rutschmann OT, Kaiser L, Gabriel V, Fathi M, Perrin L, Hirschel B. Adding saquinavir to d4T in advanced HIV-1 infection. XI International Conference on AIDS, Vancouver, July 1996, Th.B.945.
26. Cameron W. Ritonavir plus saquinavir combination therapy. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, SS5.6.
27. Hirschel B, Rutschmann O, Hathi M, Gabriel V, Mendoula A, von Overbeck I, et al. Treatment of advanced HIV infection with ritonavir plus saquinavir. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6030.
28. Workman C, Downie J, Smith DE, Sutherland D, Michelmore H, Dyer W, et al. Combination therapies in primary HIV infection. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, OP1.1.
29. Craig JC, Whittaker L, Duncan IB, et al. In vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chem Chemother 1993;4:335-9.
30. Dianzani F, Antonelli G, Turriziani O, et al. In vitro selection of human immunodeficiency virus type 1 resistant to Ro 31-8959 proteinase inhibitor. Antiviral Chem Chemother 1993;4:329-33.
31. Jacobsen H, Craig CJ, Duncan IB, et al. Molecular characterization of HIV-variants with reduced sensitivity to Ro 31-8959, a viral proteinase inhibitor. AIDS Res Hum Retroviruses 1994;10 Suppl 1:S24.
32. Turriziani O, Antonelli G, Jacobsen H, Mous J, Riva E, Pistello M, et al. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol 1994;38:297-8.
33. Tisdale M, Myers RE, Maschera B, Parry NR Oliver NM, Blair ED, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39:1704-10.
34. Eberle J, Bechowsky B, Rose D, Hansen U, von den Helm K, Gurtler L, et al. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Retroviruses 1995;11:671-6.
35. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206:527-34.
36. Roberts NA. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995;9 Suppl 2:S27-S32.
37. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, 12.
38. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. JVirol 1995;69:5228-35.
39. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
40. Race E, Gilbert SM, Tomlinson PW, Whittaker L, Moffat A, Jupp R, et al. Long term treatment with saquinavir (invirase) does not lead to a significant reduction in sensitivity to MK-639. XI International Conference on AIDS, Vancouver, July 1996, Tu.B.2124.
41. Williams PEO, Sampson AP, Green CP, et al. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol 1992;34:155P-156P.
42. Muirhead GJ, Shaw T, Williams PEO, et al. Pharmacokinetics of the HIV-proteinase inhibitor, Ro 31-8959, after single and multiple oral doses in healthy volunteers. Br J Clin Pharmacol 1992;34:170P-171P.
43. Shaw TM, Muirhead GJ, Parish N, et al. Tolerability and pharmacokinetics of single oral doses of Ro 31-8959, an HIV proteinase inhibitor. Br J Clin Pharmacol 1994;34:166P-167P.
44. Farrar G, Mitchell AM, Hooper H, et al. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from in vitro data. Br J Clin Pharmacol 1994;38:162P.
45. Kodjo A, Dumitrescu L, Crivat M, Trout H, Dohin E, Vittecoq D, et al. Digestive absorption of saquinavir in AIDS patients with severe diarrhea or wasting syndrome. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, P24.
46. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A27.
47. Norbeck D, Kumar G, Marsh K, Rodrigues D, McDonald E, Molla A, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV protease inhibitors. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995, LB7.
48. Hsu A, Granneman GR, Sun E, Chen P, El-Shourbagy T, Locke C, et al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6041.
49. Merry C, Barry M, Mulcahy F, Heavey J, Tjia J, Gibbons S, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in patients with HIV disease. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, OP6.1.
50. Anonymous. Saquinavir package insert.
51. Vacca JP, Guare JP, de Solms SJ, Sanders WM, Giuliani EA, Young SD, et al. L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. JMed Chem 1991;34:1225-8.
52. Lyle TA, Wiscount CM, Guare JP, Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. J Med Chem 1991;34:1228-30.
53. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem 1994;37:3443-51.
54. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994;90:4096-4100.
55. Balani SK, Arison BH, Mathai L, Kauffman LR, Miller RR, Stearns RA, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995;23:266-70.
56. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
57. Chodakewitz J, Deutsch P, Leavitt R, Massari F, Hildebrand C, Justice S, et al. Preliminary evaluation of the long term safety and antiviral activity exerted by Crixivan (MK-639), an oral HIV protease inhibitor. V European Conference on Clinical Aspects and Treatment of HIV Infection, Copenhagen, September 1995, abstract 43.
58. Mellors J. A randomized, double-blind study of the oral HIV protease inhibitor, L-735,524 vs. AZT in p24 antigenemic, HIV-1 infected patients with < 500 CD4 cells. 2nd National Conference on Human Retroviruses, Washington DC, 1995, 183.
59. Steigbigel R, Berry P, Teppler H, Mellors J, Drusano G, Leavitt R, et al. Extended follow-up of patients in a study of indinavir at 800 mg q8h (2.4 g/day), 1000 mg q8h (3.0 g/day) and 800 mg q6h (3.2 g/day). XI International Conference on AIDS, Vancouver, July 1996, Mo.B.412.
60. Mueller BU, Smith S, Sleasman J, Nelson Jr RP, Meyer C, Deutsch P, et al. A phase I/II study of the protease inhibitor indinavir (MK-0639) in children with HIV Infection. XI International Conference on AIDS, Vancouver, July 1996, We.B.554.
61. Chodakewitz JA, Leavitt R, Massari F, Hildebrand C, Arcuri K, Gilde L, et al. Crixivan: summary of 24-week experience with Crixivan at 2.4 g/d in phase II trials. XI International Conference on AIDS, Vancouver, July 1996, Mo.B. 1144.
62. Gulick RM, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). XI International Conference on AIDS, Vancouver, July 1996, Th.B.931.
63. Massari F, Staszewski S, Berry P, Kahn J, Frank I, Heath-Chiozzi M, et al. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine naive patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995, LB6.
64. 3. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6017.
65. 3. XI International Conference on AIDS, Vancouver, July 1996, LB.B.6019.
66. Leavitt R, Massari F, Nessly M, Meibohm A, Getson A, Chodakewitz J. Antiviral activity of indinavir (IDV) plus zidovudine (ZDV) compared to IDV or ZDV alone in antiretroviral naive patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, I109.
67. Falloon J, Owen C, Kovacs J, Leavitt R, Metcalf J, Lane HC. MK-639 (Merck HIV protease inhibitor) with interleukin-2 (IL2) in HIV. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995, I86.
68. Falloon J, Owen C, Metcalf J, Fyfe G, Lane HC. Indinavir and interleukin-2 in HIV: one year follow-up. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, I108.
69. Anonymous. AIDS/HIV treatment directory. 1996;8:42-3.
70. Condra JH, Holder DJ, Schleif WA, Chodakewitz JA, Massari FE, Blahy OM, et al. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. XI International Conference on AIDS, Vancouver, July 1996, Th.B.932.
71. Anonymous. Indinavir package insert.
72. Squires KE, Saag MS, Teppler H, Pomerantz R, Waldman S, Bjornsson T, et al. Ftiase I studies of L-735,524, an HIV protease inhibitor: pharmacokinetics, tolerability and short-term antiviral activity. Clin Res 1994;42:280A.
73. Waldman SA, Teppler H, Osborne B, Bjornsson TD, Pomerantz R, Woolf E, et al. Pharmacokinetics of L-735,524, an HIV protease inhibitor. Clin Pharmacol Ther 55:195 (PIII-52).
74. Anonymous. Data on file MSD.
75. The Indinavir (MK639) Pharmacokinetic Study Group, Merck Research Labs. Indinavir (MK 639) drug interaction studies. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.174.
76. De Wit S, Turner D, Debier M, Desmet M, Mc Crea J, Matthews C, et al. Absence of interaction between indinavir and fluconazole; a pharmacokinetic study in HIV patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A26.
77. Committee for Proprietary Medicinal Products. European Public Assessment Report (EPAR). Norvir. 16 August 1996, CPMP/527/96.
78. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl JMed 1995;333:1528-33.
79. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
80. Hicks CB, Lehman L, Eron, Horton J, Jemsek J, Kelly N, et al. Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.415.
81. Mueller BU, Zuckerman J, Nelson Jr RP, Sleasman J, Vora S, Saulis R, et al. A phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection. XI International Conference on AIDS, Vancouver, July 1996, We.B.551.
82. Cameron B, Heath-Chiozzi M, Kravick S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. Update. XI Conference on AIDS, Vancouver, July 1996, Mo.B.411.
83. Heath-Chiozzi M, Leonard J, Sun E, Lehman L, Henry D, Kravcik S, et al. Ritonavir clinical benefit correlates with HIV RNA and CD4 cell levels in advanced HIV illness. XI International Conference on AIDS, Vancouver, July 1996, We.B.3127.
84. Mathez D, Bagnarelli P, De Truchis P, Gorin I, Katlama C, Raloux G, et al. A triple combination of ritonavir + AZT + ddC as a first line treatment of patients with AIDS: update. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.175.
85. Notermans DW, de Wolf F, Foudraine NA, Meenhorst PL, Kauffman RH, McDade H, et al. The effects of an antiretroviral triple combination with ritonavir, AZT and 3TC. 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996, OP8.2.
86. Danner SA. Immediate versus delayed triple therapy with ritonavir, AZT and 3TC. Abbott Satellite Symposium, 3rd International Congress on Drug Therapy in HIV Infection, Birmingham, November 1996.
87. Markowitz M, Cao Y, Hurley A, O'Donovan R, Heath-Chiozzi M, Leonard J, et al. Triple therapy with AZT, 3TC and ritonavir in 12 subjects newly infected with HIV-1. XI International Conference on AIDS, Vancouver, July 1996, Th.B.933.
88. Korneyeva M, Molla A, Kempf D, Vasavanonda S, Chernyavskia T, Boucher C, et al. Clinical and virological responses to ritonavir, an inhibitor of HIV protease. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1137.
89. Hsu A, Granneman R, Rynkiewicz K, Valdes J, Mayer K, Leonard J Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses. American Association of Pharmaceutical Scientists Ninth Annual Meeting & Exposition, San Diego, November 1994, PPDM 8272.
90. Bertz R, Shi H, Cavanaugh J, Hsu A. Effect of three vehicles, Advera®, Ensure®, and chocolate milk, on the bioavailability of an oral liquid formulation of Norvir® (ritonavir). 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 1996, A25.
91. Molla A, Kempf D, Korneyeva M, et al. Characterization of the in vivo resistance pathway and pharmacokinetic properties of ritonavir. Vth International Workshop on HIV Drug Resistance, Whistler, July 1996, Abstract 31.
92. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1137.
93. Ouellet D, Hsu A, Qian J, Cavanaugh J, Leonard J, Granneman GR. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1198.
94. Cato A, Cavanaugh JH, Shi H, Hsu A, Granneman GR, Leonard J Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1199.
95. Sun E, Heath-Chiozzi M, Cameron DW, Hsu A, Granneman RG, Maurath CJ, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse effects. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.171.
96. Hsu A, Granneman GR, Witt G, Cavanaugh JH, Leonard J. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1200.
97. Bertz RJ, Cao G, Cavanaugh JH, Hsu A, Granneman GR, Leonard JM. Effect of ritonavir on the pharmacokinetics of desipramine. XI International Conference on AIDS, Vancouver, July 1996, Mo.B.1201.
98. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1995.
99. Anonymous. Ritonavir package insert.